Brokerages Set Insulet Co. (NASDAQ:PODD) Price Target at $239.18

Shares of Insulet Co. (NASDAQ:PODD) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $239.18.

Several brokerages have commented on PODD. Redburn Atlantic began coverage on shares of Insulet in a research report on Thursday, May 30th. They set a “buy” rating and a $235.00 price target on the stock. Wolfe Research raised shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target on the stock in a research report on Tuesday, May 7th. Raymond James cut their price target on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. OTR Global reaffirmed a “mixed” rating on shares of Insulet in a report on Monday, June 10th. Finally, Barclays dropped their target price on shares of Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a report on Monday, May 13th.

Insulet Price Performance

Shares of PODD stock opened at $201.80 on Thursday. Insulet has a 12-month low of $125.82 and a 12-month high of $295.00. The firm has a market capitalization of $14.13 billion, a price-to-earnings ratio of 61.15, a price-to-earnings-growth ratio of 3.73 and a beta of 1.14. The company has a quick ratio of 2.75, a current ratio of 3.74 and a debt-to-equity ratio of 1.72. The firm has a fifty day moving average of $183.59 and a 200-day moving average of $186.47.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.34. The firm had revenue of $441.70 million during the quarter, compared to analyst estimates of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The company’s revenue for the quarter was up 23.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.23 EPS. On average, equities research analysts forecast that Insulet will post 3.11 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Timothy J. Scannell sold 7,000 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.51, for a total transaction of $1,333,570.00. Following the sale, the director now owns 35,586 shares in the company, valued at approximately $6,779,488.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Insulet news, Director Timothy J. Scannell sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.51, for a total value of $1,333,570.00. Following the sale, the director now owns 35,586 shares in the company, valued at $6,779,488.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mark N. Field sold 2,131 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $190.43, for a total transaction of $405,806.33. Following the completion of the sale, the senior vice president now owns 14,375 shares in the company, valued at approximately $2,737,431.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,931 shares of company stock worth $2,636,286. Corporate insiders own 0.47% of the company’s stock.

Hedge Funds Weigh In On Insulet

Large investors have recently modified their holdings of the business. Parkside Financial Bank & Trust raised its stake in shares of Insulet by 251.0% during the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 123 shares during the last quarter. Sunbelt Securities Inc. bought a new position in shares of Insulet during the first quarter valued at $29,000. Wolff Wiese Magana LLC raised its stake in shares of Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 134 shares during the last quarter. Benjamin F. Edwards & Company Inc. bought a new position in shares of Insulet during the fourth quarter valued at $34,000. Finally, Jones Financial Companies Lllp bought a new position in shares of Insulet during the fourth quarter valued at $40,000.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.